SCHEMBL21056897

SCHEMBL21056897

O=C(O)c1ccncc1Oc1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
KDM4C Q9H3R0 7/20 0.49
XDH P47989 1/20 0.47
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
KDM6B O15054 1/20 0.45
KDM4A O75164 1/20 0.45
THRB P10828 1/20 0.45
KDM4D Q6B0I6 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ICAM1 P05362 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238351 0.85 KDM4C (0.59) KDM4CMAPTKMT2AL3MBTL1ALDH1A1
SCHEMBL22868033 0.84 PTGS1 (0.52) CA1CA2KDM4CMAPTLMNA
SCHEMBL17820304 0.80 ALDH1A1 (0.47) CA1CA2KDM4CMAPTLMNA
SCHEMBL2865011 0.78 CTNNB1 (0.58) MAPTLMNAHTTKMT2AL3MBTL1
SCHEMBL4450925 0.77 PTGER4 (0.49) XDHKDM4ETSPO
SCHEMBL9165102 0.74 KDM4C (0.47) KDM4CMAPTLMNAKMT2AL3MBTL1
SCHEMBL4445272 0.73 PTGER4 (0.59) XDHKDM4E
SCHEMBL9339488 0.73 CA12 (0.53) CA12CA1CA2CA9MAPT
SCHEMBL9339489 0.73 CA12 (0.53) CA12CA1CA2CA9MAPT
SCHEMBL944347 0.73 CTNNB1 (0.65) KDM4CMAPTHTTKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
CN-112105354-A Fibroblast activation protein inhibitor 普拉西斯生物技术有限责任公司 2020-12-18 CN disclosed
EP-3723753-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2020-10-21 EP disclosed
WO-2019118932-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2019-06-20 WO disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 US disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 CA12 4423/4885CA1 4653/4885CA2 2997/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 CA12 4423/4885CA1 4653/4885CA2 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.